DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,952,900 | +4.9% | 177,158 | +1.6% | 2.56% | +6.6% |
| Q2 2023 | $41,884,948 | -9.9% | 174,325 | -5.4% | 2.40% | -14.3% |
| Q1 2023 | $46,493,062 | -2.1% | 184,270 | +3.1% | 2.80% | -4.2% |
| Q4 2022 | $47,474,154 | -0.0% | 178,696 | -2.7% | 2.93% | -4.1% |
| Q3 2022 | $47,493,000 | +4.3% | 183,697 | +2.3% | 3.05% | +9.0% |
| Q2 2022 | $45,551,000 | -14.6% | 179,497 | -1.3% | 2.80% | -2.7% |
| Q1 2022 | $53,351,000 | -11.9% | 181,880 | -1.1% | 2.88% | -6.4% |
| Q4 2021 | $60,533,000 | -47.5% | 183,984 | -51.4% | 3.07% | +1.3% |
| Q3 2021 | $115,324,000 | +124.6% | 378,810 | +98.0% | 3.04% | +14.4% |
| Q2 2021 | $51,349,000 | +18.2% | 191,342 | -0.9% | 2.65% | +9.6% |
| Q1 2021 | $43,437,000 | -3.4% | 192,983 | -4.7% | 2.42% | -8.3% |
| Q4 2020 | $44,981,000 | +0.2% | 202,490 | -2.9% | 2.64% | -10.7% |
| Q3 2020 | $44,902,000 | +20.9% | 208,528 | -0.7% | 2.96% | +11.1% |
| Q2 2020 | $37,144,000 | +25.5% | 210,053 | -1.8% | 2.66% | +2.7% |
| Q1 2020 | $29,592,000 | -10.2% | 213,796 | -0.4% | 2.59% | +10.9% |
| Q4 2019 | $32,939,000 | +1.4% | 214,612 | -4.6% | 2.34% | -5.0% |
| Q3 2019 | $32,479,000 | +1.2% | 224,878 | +0.1% | 2.46% | -0.8% |
| Q2 2019 | $32,108,000 | +6.8% | 224,655 | -1.4% | 2.48% | +1.3% |
| Q1 2019 | $30,075,000 | +24.8% | 227,806 | -2.5% | 2.45% | +8.0% |
| Q4 2018 | $24,089,000 | -14.2% | 233,598 | -9.6% | 2.27% | +6.3% |
| Q3 2018 | $28,092,000 | +15.7% | 258,533 | +5.1% | 2.13% | +10.1% |
| Q2 2018 | $24,281,000 | +0.6% | 246,053 | -0.2% | 1.94% | -0.4% |
| Q1 2018 | $24,132,000 | +5.7% | 246,468 | +0.2% | 1.94% | +6.3% |
| Q4 2017 | $22,833,000 | +8.5% | 245,987 | +0.2% | 1.83% | +5.2% |
| Q3 2017 | $21,053,000 | +1.0% | 245,434 | -0.7% | 1.74% | -1.5% |
| Q2 2017 | $20,853,000 | -1.5% | 247,099 | -0.1% | 1.76% | -3.8% |
| Q1 2017 | $21,164,000 | +10.3% | 247,448 | +0.4% | 1.83% | +2.4% |
| Q4 2016 | $19,189,000 | +1.0% | 246,516 | +1.7% | 1.79% | +1.4% |
| Q3 2016 | $18,998,000 | -22.3% | 242,351 | +0.1% | 1.76% | -23.4% |
| Q2 2016 | $24,444,000 | +7.9% | 242,016 | +1.4% | 2.30% | +0.1% |
| Q1 2016 | $22,645,000 | +2.8% | 238,719 | +0.6% | 2.30% | +3.0% |
| Q4 2015 | $22,030,000 | +9.0% | 237,190 | -0.0% | 2.24% | +1.5% |
| Q3 2015 | $20,215,000 | +2.3% | 237,235 | +2.7% | 2.20% | +8.7% |
| Q2 2015 | $19,765,000 | +1.6% | 230,926 | +0.8% | 2.02% | +2.2% |
| Q1 2015 | $19,449,000 | -1.4% | 229,081 | -0.4% | 1.98% | +1.0% |
| Q4 2014 | $19,723,000 | +12.3% | 230,110 | -0.4% | 1.96% | +8.8% |
| Q3 2014 | $17,558,000 | -3.8% | 231,090 | -0.4% | 1.80% | -3.3% |
| Q2 2014 | $18,259,000 | +9.7% | 231,918 | +4.5% | 1.87% | -1.2% |
| Q1 2014 | $16,647,000 | +3.8% | 221,958 | +6.8% | 1.89% | -5.2% |
| Q4 2013 | $16,037,000 | +12.5% | 207,738 | +1.1% | 1.99% | +2.6% |
| Q3 2013 | $14,250,000 | +10.1% | 205,573 | +0.6% | 1.94% | -5.1% |
| Q2 2013 | $12,941,000 | – | 204,438 | – | 2.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |